These findings suggest that a higher tumor 18F-FDG uptake expressed as SUVmax predicts response to checkpoint inhibitor therapy, which can be explained by the positive correlation between PD-L1 expression and 18F-FDG uptake [27,28]. Here, CD274 is linked to neoplasm.